Rationale: ABPA occurs predominantly in individuals with asthma or CF. Standard treatment for ABPA includes oral corticosteroids and, occasionally, antifungal agents. It has been reported that omalizumab, a monoclonal anti-IgE antibody, can be an effective treatment for CF patients with ABPA.
Methods: We performed a retrospective chart review on three adolescent CF patients who were diagnosed with ABPA and treated with omalizumab.
Patients 1 and 2 presented with pulmonary exacerbations, diminishing FEV1, and abnormal chest radiographs. Pseudomonas
Results: Additional investigation revealed skin test positivity to A.
Conclusions: Omalizumab may be an effective, alternative therapy for ABPA in CF patients who fail to respond to systemic corticosteroids or have contraindications to its use.
Full conference title:
- AAAAI 2017 (73rd)